Comparing the current results to its competitors, Paragon 28 Inc reported Revenue increase in the 4 quarter 2024 by 20.53 % year on year. The sales growth was above Paragon 28 Inc 's competitors' average revenue growth of 5.25 %, achieved in the same quarter.
Paragon 28 inc , slower than the average decrease reported by the company's competitors of -37.43 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -37.43 %
Paragon 28 Inc 's Comment on Competition and Industry Peers
Paragon 28 operates exclusively in the foot and ankle market, differentiating itself from competitors that serve multiple orthopedic indications. The foot and ankle market is primarily led by multinational companies that also participate in broader medical device and orthopedic sectors. Key competitive factors in this market include product features, technological advancements, physician training, product quality, patient experience, pricing, clinical outcomes, intellectual property, and customer service. Major competitors in the lower extremities market include Stryker Corporation, Arthrex, Inc., Smith & Nephew plc, Johnson & Johnson, and Zimmer Biomet Holdings, Inc. Additional competitors with limited foot and ankle product offerings include Enovis Medical, Medline Industries, Inc., Conmed Corporation, and Treace Medical Concepts, Inc. These companies possess substantial financial resources and compete in areas such as market share, talent recruitment, research and development, product launches, and technology acquisition. Paragon 28 also faces competition from international medical device manufacturers that may develop effective or lower-cost products and obtain regulatory clearance ahead of Paragon 28.
September 21, 2024
Legal Labyrinth: Shareholders of Paragon 28 Urged to Explore Their Rights Amid Potential Misinformation By Published: September 21, 2024 New York, NY In a world where transparency is the cornerstone of investor confidence, shareholders of Paragon 28, Inc. (NYSE: FNA) find themselves at a critical juncture. The Rosen Law Firm, revered globally for its relentless advocacy of investor rights, has issued a clarion call for those who have suffered losses in Paragon 28 stock. The firm is now rigorously investigating potential securities claims that revolve around allegations of materially misleading business information allegedly dispensed by Paragon 28 to the general investing populace. A Hard Hit to Tru...
August 1, 2024
In a notable development on the corporate governance landscape, the Johnson Fistel law firm has announced an investigation into Paragon 28, Inc. (NYSE: FNA), a company specializing in innovative orthopedic solutions. This comes amid concerns of potentially serious breaches in securities laws that may have adversely affected shareholders. The probe, announced on August 1, 2024, signals a growing scrutiny of corporate practices amid increasing calls for transparency and accountability in public companies. Background: Who is Paragon 28, Inc. Founded in 2018 and headquartered in Englewood, Colorado, Paragon 28 has made significant strides in the orthopedic market, particularly focusing on solutions for foot and ...
February 1, 2024
Paragon 28 (NYSE: FNA), a global leader in orthopedic medical device innovation, has announced the release of several technology-based surgical systems that aim to improve patient outcomes and speed recovery time with minimally invasive procedures. The company s newly launched PRECISION MIS Bunion System provides surgeons with a guided technique for carrying out a distal metatarsal osteotomy. The system uses a minimally invasive surgical (MIS) technique and features specific instrumentation designed to achieve a controlled tri-planar correction, including adjustments to the distal metatarsal articular angle, translation, and derotation of the metatarsal head.Meanwhile, the Englewood, Colorado-based firm als...
January 30, 2024
Paragon 28 Launches Innovative Solutions for Foot and Ankle SurgeryParagon 28, Inc. (NYSE: FNA) recently introduced two groundbreaking products, the FJ2000 Power Console and Burr System, designed specifically for minimally invasive and open foot and ankle procedures. The power console and burr system offer versatility and efficient setup, with three pre-set options for different procedure requirements.In addition to this launch, Paragon 28 also announced the limited market release of its Bun-Yo-Matic Lapidus Clamp System. This innovative system allows surgeons to simulate weight-bearing and apply compression before hardware application, making the procedure more reproducible and efficient. The first surgical...
January 26, 2024
In a groundbreaking move towards minimally invasive procedures, medical technology company Paragon 28, Inc. has introduced the Mister Tendon Harvester System. This innovative system allows surgeons to perform distal cuts of the flexor hallucis longus (FHL) or flexor digitorum longus (FDL) tendon through a small incision, facilitating tendon transfer procedures. By enabling better healing and faster recovery, this pioneering technology promises to reshape the landscape of tendon surgeries.Innovating the Tendon Harvesting Landscape:Traditional tendon transfer procedures, involving the relocation of tendons for enhanced functionality, have long relied on large incisions that often result in prolonged post-opera...
January 17, 2024
Paragon 28, a leading medical device company, is proud to announce the limited market release of its groundbreaking Bun-Yo-Matic Lapidus Clamp System. Marking a significant advancement in the field of bunion surgery, this innovative system has already witnessed successful surgical cases in Orange County, California, and Seattle, Washington. With its ability to simulate weight-bearing and offer compression prior to hardware application, the Bun-Yo-Matic is set to revolutionize Lapidus Bunion Procedures.Developed by the expert team at Paragon 28, the Bun-Yo-Matic is the first-of-its-kind bunion solution available in the market. This cutting-edge clamp and cut guide system is designed to provide surgeons with a...
Procept Biorobotics Corporation follows a business model focused on developing medical robotics solutions for urology procedures. Their flagship product, the AquaBeam System, utilizes waterjet technology to perform minimally invasive surgeries for patients with benign prostatic hyperplasia. The company aims to improve patient outcomes and reduce healthcare costs by providing an innovative and efficient alternative to traditional surgical methods.
Orthofix Medical Inc is a company that focuses on developing and selling medical devices and orthopedic solutions to healthcare providers and patients.
Monogram Orthopaedics Inc. operates on a specialized business model focused on developing and manufacturing innovative orthopedic medical devices. With a strong emphasis on research and development, they design cutting-edge solutions to address various musculoskeletal conditions. The company collaborates with healthcare professionals to test and refine their products, ensuring their efficacy and safety for patients.
Sources:
Paragon 28 inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Paragon 28 inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
